←Pulmonary & Critical Care
Pulmonary embolism
📚
📚 Library › 🫁 Pulmonary & Critical Care › Pulmonary vascular
🩸

Pulmonary embolism

Pretest probability, age-adjusted D-dimer, risk classes, who gets lysis, DOAC dosing and duration.

PEWellsD-dimerPESIthrombolysis
🗓️ Reviewed 2026-11-18 · ⏱️ 4 min read · 📖 2019 ESC PE guideline · 2021 CHEST VTE guideline · 2020 ASH VTE guideline
🧠 Pathophysiology in 60 seconds🔎 Diagnosis🧪 Risk stratification💊 Management⚠️ Pitfalls🎓 Board corner📚 References
⚡ Bottom line — first hour
  • Pretest probability first (Wells / clinical gestalt). Low → PERC or age-adjusted D-dimer (age × 10 if >50).
  • High probability → CTPA (start anticoagulation while you wait if bleed risk is low).
  • Risk-stratify: shock? → high risk → systemic lysis (alteplase 100 mg / 2 h). RV strain + troponin → intermediate-high → monitor, rescue lysis if crash.
  • Most patients → DOAC (apixaban 10 mg BID × 7 d → 5 mg BID). Low-risk (sPESI 0) → early discharge.
  • Activate the PERT for intermediate-high and high risk.

🧠 Pathophysiology in 60 seconds

⌄
  • Virchow: stasis + endothelial injury + hypercoagulability → DVT (mostly proximal leg) → embolizes.
  • Clot raises pulmonary vascular resistance → RV pressure overload → RV dilates, septum shifts left → LV underfilled → low output → shock.
  • RV ischemia (high wall stress + low coronary flow) → troponin up → death spiral.
  • Hypoxemia from V/Q mismatch; dead space → high minute ventilation, low PaCO₂.
🧩 Think of it like this

The RV is a thin-walled sprinter, not a weightlifter. Ask it to push against a sudden clot and it fails fast. That is why RV size on echo predicts outcome.

🔎 Diagnosis

⌄
Wells criteria Points
Clinical signs of DVT 3
PE most likely diagnosis 3
HR >100 1.5
Immobilization ≥3 d or surgery <4 wk 1.5
Prior DVT/PE 1.5
Hemoptysis 1
Cancer (active) 1

≤4 = PE unlikely → D-dimer. >4 = likely → CTPA.

  • PERC (all 8 negative in low gestalt → no testing): age <50, HR <100, SpO₂ ≥95%, no hemoptysis, no estrogen, no prior VTE, no unilateral leg swelling, no recent surgery/trauma.
  • YEARS algorithm: 0 items → D-dimer <1000 rules out; ≥1 → <500.
  • CTPA contraindicated → V/Q scan (normal CXR) or leg Doppler (positive DVT = treat).
  • ECG: sinus tachycardia (most common), S1Q3T3, RV strain, new RBBB.

🧪 Risk stratification

⌄
Low risksPESI 0, normal RV➡️ DOAC, early discharge
IntermediateRV strain ± troponin↑➡️ heparin, watch closely
High risk (massive)SBP <90 ≥15 min / shock➡️ systemic lysis or catheter / surgery
Tool Low-risk if
sPESI 0 points: age ≤80, no cancer, no chronic cardiopulmonary disease, HR <110, SBP ≥100, SpO₂ ≥90%
Hestia All 11 criteria negative → outpatient
RV on CT/echo RV/LV ratio <1.0
Troponin / BNP Normal

💊 Management

⌄
Drug Dose
Apixaban 10 mg BID × 7 d → 5 mg BID
Rivaroxaban 15 mg BID × 21 d → 20 mg daily (with food)
Enoxaparin 1 mg/kg SC q12h (→ DOAC or warfarin)
UFH 80 U/kg bolus → 18 U/kg/h — use if lysis/procedure may be needed, CrCl <30, unstable
Dabigatran / edoxaban After ≥5 d of parenteral therapy
  • Cancer-associated VTE: apixaban, rivaroxaban, edoxaban or LMWH (caution GI/GU cancers with bleeding).
  • Avoid DOACs: antiphospholipid syndrome (triple positive) → warfarin; pregnancy → LMWH.
  • Systemic alteplase 100 mg IV over 2 h (stop heparin during infusion, then restart).
  • Cardiac arrest from PE → alteplase 50 mg bolus, continue CPR 60–90 min.
  • Contraindicated / failed → catheter-directed therapy or surgical embolectomy; VA-ECMO bridge.
  • Avoid big fluid boluses (RV is overloaded); norepinephrine for hypotension; avoid intubation if possible (positive pressure → collapse).
Situation Duration
Major transient provoker (surgery, trauma) 3 months
Minor/transient (travel, estrogen) 3 months, consider longer
Unprovoked Extended (indefinite) if bleeding risk acceptable; reduced-dose apixaban 2.5 mg BID after 6 mo is an option
Active cancer While cancer active
Recurrent VTE Indefinite
  • IVC filter only if anticoagulation is contraindicated (remove later).
  • Subsegmental, single, no DVT, low risk → surveillance can be discussed.

⚠️ Pitfalls

⌄
  • D-dimer in high-probability patients (a negative does not rule out).
  • Withholding anticoagulation while waiting hours for CT in high suspicion.
  • Fluids for RV failure shock.
  • Thrombophilia testing during the acute event (results unreliable on heparin/acute clot).

🎓 Board corner

⌄
Stem Answer
PE, BP 75/40 Systemic thrombolysis
PE, normal BP, RV dilation + troponin up Anticoagulate, monitor; rescue lysis if worsens
PE + active GI bleed IVC filter
Pregnant, suspected PE Leg Doppler / CTPA or V/Q; treat with LMWH
Unprovoked PE, done 6 months, low bleed risk Continue (extended) anticoagulation
Triple-positive APS Warfarin, not DOAC

📚 References

⌄
  • Konstantinides SV, et al. 2019 ESC Guidelines for acute PE. Eur Heart J. 2020;41:543.
  • Stevens SM, et al. CHEST Guideline: Antithrombotic Therapy for VTE (2nd update). Chest. 2021;160:e545.
  • Ortel TL, et al. ASH 2020 guidelines for VTE treatment. Blood Adv. 2020;4:4693.
↩︎ Back to 🫁 Pulmonary & Critical Care